Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 16, 2012

View Archived Issues

Chong Kun Dang Pharmaceutical divulges new CETP inhibitors

Researchers at Nutek Pharma prepare new anesthetic agents

Phase I trial of IMO-8400 begins, preclinical results presented

PTC-596 shows efficacy in a number of tumor models in vivo

Data presented on a novel EGFR inhibitor for patients with lung cancer

AstraZeneca will not exercise the option to acquire diabetes assets from Prosidion

Evotec and Haplogen partner to develop drugs for viral infectious diseases

Plasma ADMA as a biomarker to monitor PAH-targeted treatments

Tranzyme Pharma reports topline results from TZP-102 trial

TissueGene completes enrollment in phase II study of TG-C

Inovio Pharmaceuticals expands synthetic vaccine license with University of Pennsylvania

Bavarian Nordic's MVA-BN vaccine platform receives U.S. government contracts

Chinese researchers present new agents for HIV

Nanosphere receives FDA clearance to market test for CYP2C19 mutation

Merck & Co. prepares new NS5B inhibitors

RXi reports pharmacokinetic results from phase I study of candidate for dermal scarring

U.S. Department of Health & Human Services reports novel PLK1 inhibitor compounds

DNDi identifies chemical series targeting two neglected diseases

Epizyme and Eisai patent novel agents for cancer

Fujifilm provides update on development of micro-needle array delivery technology

Forest Laboratories and Adamas to develop fixed-dosed combination for Alzheimer's

Positive in vivo results support the advance of TVB-2640 into clinical studies

Immunovative Therapies expands collaboration with the University of Arizona

Investigators begin study of CNDO-201 in autism spectrum disorders

FDA approves Zilver PTX drug-eluting stent for peripheral arterial disease

New causative gene identified for primary torsion dystonia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...